ATMI Reports Fourth Quarter 2012 Results

company logo

DANBURY, Conn., Feb. 6, 2013 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI) today reported revenues and net income for the fourth quarter of 2012.

Revenues improved 11 percent to $100.1 million during the fourth quarter of 2012 compared with $90.3 million during the prior year period. Net income for the quarter was $12.6 million, or $0.39 per diluted share, including a gain of $0.07 per diluted share for a contingent consideration adjustment, compared with a loss of $47.2 million, or $1.49 per diluted share, during the prior year period due to a one-time $84.6 million pre-tax charge ($1.68 per diluted share) related to the SDS Direct transaction.

"Fourth quarter revenues grew as the incremental contribution from our SDS Direct transaction last year more than offset the negative effects of lower wafer starts," said Doug Neugold, Chief Executive Officer. "Demand for other products in Microelectronics was down as lower wafer starts were coupled with our customers' efforts to manage inventory at the end of the year. LifeSciences revenues grew 20% over the prior year quarter as customers continue to make progress toward launching high-volume manufacturing using our single-use technologies."

Cash, including marketable securities, was $168.5 million at the end of the quarter, an increase of $29.3 million from the third quarter of 2012. Net cash provided by operating activities was $39.8 million due to strong earnings and effective working capital management. Capital expenditures were $10.9 million as spending increased on the new manufacturing plant in Korea.

Fourth Quarter Segment Results


  • Revenues were $89.1 million, up 10 percent compared with last year
  • Incremental contribution from SDS Direct offset lower wafer starts and inventory management by our customers
  • Operating income was $23.4 million


  • Revenues improved 20 percent compared with last year to $10.9 million
  • Continued demand for single-use products drove the improvement
  • Operating income of $1.3 million includes a contingent consideration benefit of $2.4 million related to a reduction in the earnout associated with the 2010 Artelis acquisition

Market Environment

"We expect wafer starts to grow modestly for the full year of 2013, with most growth occurring during the second half of the year after declining sequentially in the first quarter due to seasonal patterns," commented Neugold. "As always, our intent is to grow more rapidly than wafer starts by focusing on new products for leading-edge technology nodes. In LifeSciences, while there is uncertainty in the timing associated with ramping a new technology, we believe growth should be within our long-term expectations as customers continue to ramp manufacturing processes incorporating our single-use mixing and bioreactor systems. Finally, as we continue to generate cash we are well positioned to invest in growth opportunities and create value for our shareholders."

Webcast Information

A conference call (dial-in: 877.766.0748) discussing the Company's financial results and business outlook will begin at 11:00 a.m. Eastern time, February 6, 2013. A replay of the call will be available for 48 hours at 855.859.2056 (access code 93634152). An audio webcast of the conference call will be available for 30 days on

About ATMI

ATMI, Inc. provides specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the worldwide semiconductor, flat panel, and life sciences industries. For more information, please visit

The ATMI, Inc. logo is available at

ATMI, the ATMI logo, and SDS are trademarks or registered trademarks of Advanced Technology Materials, Inc., in the United States, other countries, or both.

Forward Looking Statements

Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor and life sciences industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing, and delivering new products; customer-driven pricing pressure; potential loss of key customers; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; ability to protect ATMI's proprietary technology; and other factors described in ATMI's Form 10-K for the year ended December 31, 2011 and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.

(in thousands, except per share data)
Three Months Ended Twelve Months Ended
December 31, December 31,
2012 2011 2012 2011
(Unaudited) (Unaudited) (Unaudited)
Revenues $100,113 $90,330 $407,433 $390,087
Cost of revenues 51,322 47,804 206,543 205,957
Gross profit 48,791 42,526 200,890 184,130
Operating expenses:
Research and development 14,566 13,249 55,152 53,708
Selling, general, and administrative 18,696 21,323 86,663 83,546
Contract termination -- 84,590 -- 84,590
Total operating expenses 33,262 119,162 141,815 221,844
Operating income (loss) 15,529 (76,636) 59,075 (37,714)
Other income (expense), net 637 (1,332) 1,051 (1,420)
Income (loss) before income taxes 16,166 (77,968) 60,126 (39,134)
Income tax provision (benefit) 3,546 (30,767) 17,796 (19,115)
Net income (loss) $12,620 ($47,201) $42,330 ($20,019)
Earnings (loss) per diluted share $0.39 ($1.49) $1.30 ($0.63)
Weighted average shares
Outstanding - diluted 32,679 31,709 32,664 31,703
(in thousands)

December 31,

December 31,
Cash & marketable securities (1) $156,447 $110,155
Accounts receivable, net 60,806 51,563
Inventories, net 87,555 73,622
Other current assets 25,736 35,848
Total current assets 330,544 271,188
Property, plant, and equipment, net 125,099 116,275
Marketable securities, non-current (1) 12,073 3,329
Other assets 131,437 122,894
Total assets $599,153 $513,686
Liabilities and stockholders' equity
Accounts payable $38,573 $20,779
Other current liabilities 36,329 24,177
Total current liabilities 74,902 44,956
Non-current liabilities 16,975 18,399
Stockholders' equity 507,276 450,331
Total liabilities & stockholders' equity $599,153 $513,686
(1) Total cash and marketable securities equaled $168.5 million and $113.5 million at December 31, 2012 and December 31, 2011, respectively.
Segment Results
(in thousands)
Three Months Ended Twelve Months Ended
December 31, December 31,
2012 2011 2012 2011
Microelectronics $ 89,055 $ 81,147 $ 365,515 $ 351,417
LifeSciences 10,933 9,127 41,584 38,264
All Other 125 56 334 406
Total Consolidated $ 100,113 $ 90,330 $ 407,433 $ 390,087
Operating income (loss)
Three Months Ended Twelve Months Ended
December 31, December 31,
2012 2011 2012 2011
Microelectronics $ 23,442 $ (63,785) $ 109,259 $ 13,079
LifeSciences 1,301 (1,405) (4,066) (5,954)
All Other (9,214) (11,446) (46,118) (44,839)
Total Consolidated $ 15,529 $ (76,636) $ 59,075 $ (37,714)

CONTACT: Troy Dewar Director, Investor Relations 203.207.9349

Source:ATMI, Inc.